SDGR — Schrodinger, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1490978 ·
Last close
$28.85
Market Cap
$1.89B
52W High
$31.59
52W Low
$10.94
ADV30
1,781,063
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 58,889,000 | 32,432,000 | -41,547,000 | 5,975,000 | 640,394,000 | 287,853,000 | 311,438,000 |
| Mar 2026 | 58,587,000 | 29,547,000 | -48,794,000 | -60,026,000 | 634,187,000 | 260,255,000 | 320,639,000 |
| Dec 2025 | 87,235,000 | 57,293,000 | -17,157,000 | 32,511,000 | 726,160,000 | 230,517,000 | 362,107,000 |
| Sep 2025 | 54,324,000 | 28,039,000 | -45,947,000 | -32,795,000 | 653,660,000 | 172,120,000 | 332,308,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-126,870,000
Investing CF
$186,083,000
Financing CF
$1,723,000
CapEx
$-3,401,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.77
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-682,857,000
Inventory
—
Receivables
$41,124,000
ST Investments
$125,886,000
EBIT TTM
$-153,445,000
Pretax Income TTM
$-51,931,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$259,035,008
EBITDA
$-147,579,008
Free Cash Flow
$-29,163,124
Enterprise Value
$1,117,067,008
Total Cash
$413,739,008
Total Debt
$108,003,000
Shares Out
65,641,435
Trailing EPS
$-0.73
Book Value
$4.51
ROE
-16.2%
ROA
-14.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 255,869,000 | -166,896,000 | -103,265,000 | 726,160,000 | 362,107,000 | 364,053,000 | 13,899,000 |
| Dec 2024 | 207,539,000 | -209,296,000 | -187,123,000 | 823,226,000 | 401,781,000 | 421,445,000 | -157,368,000 |
| Dec 2023 | 216,666,000 | -177,448,000 | 40,720,000 | 802,955,000 | 254,397,000 | 548,558,000 | -136,733,000 |
| Dec 2022 | 180,955,000 | -146,817,000 | -149,186,000 | 688,587,000 | 240,682,000 | 447,894,000 | -119,683,000 |
TTM Snapshot
Revenues TTM
$174,390,000
NetIncome TTM
$-199,821,000
OpCashFlow TTM
$0
Assets (Latest)
$726,160,000
Forward EPS
$-1.35
Max Pain — expiry 2026-10-16
max pain strike: $25.00 · spot: $29.27 · call oi: 14,685 · put oi: 2,036
Expected Move to 2026-10-16:
±$4.68
(15.97%) —
implied range
$24.60 –
$33.95
· ATM straddle on $30.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GRFS | Grifols SA | $1.90B | $7.35 | — |
| ZYME | Zymeworks Inc. | $1.88B | $26.52 | — |
| GENB | Generate Biomedicines, Inc. | $1.94B | $15.15 | — |
| AGIO | AGIOS PHARMACEUTICALS, INC. | $1.95B | $32.58 | — |
| NKTR | NEKTAR THERAPEUTICS | $1.95B | $57.06 | — |
News headlines (Yahoo Finance, 1h cache)
Schrodinger Stock Has Technical Strength as It Hits New 2-Year Highs
2026-09-23 17:50 · Yahoo
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-09-17 12:30 · Yahoo
Schrodinger (SDGR) Soars 12.1%: Is Further Upside Left in the Stock?
2026-09-16 10:51 · Yahoo
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs
2026-09-09 11:00 · Yahoo
Schrödinger to Present at Morgan Stanley Global Healthcare Conference
2026-09-01 12:30 · Yahoo
Schrodinger Q2 Earnings Call Highlights
2026-08-06 05:03 · Yahoo
Schrodinger, Inc. (SDGR) Q2 Earnings and Revenues Top Estimates
2026-08-06 00:35 · Yahoo
Schrödinger (SDGR) Could Be 29% Below Fair Value Despite A 38% Overvalued View
2026-09-27 20:05 · Yahoo
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
2026-09-24 15:08 · Yahoo
Why DataMEDS’ Acquisition Does Not Seem to Be Very Bullish for MEDS Stock at This Point
2026-09-18 22:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.